Cover Image
市場調查報告書

白細胞介素1受體類型1:開發中產品分析

Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) - Pipeline Review, H1 2018

出版商 Global Markets Direct 商品編碼 520768
出版日期 內容資訊 英文 53 Pages
訂單完成後即時交付
價格
Back to Top
白細胞介素1受體類型1:開發中產品分析 Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) - Pipeline Review, H1 2018
出版日期: 2018年06月15日 內容資訊: 英文 53 Pages
簡介

本報告提供以白細胞介素1受體類型1為標的之治療藥開發平台現狀及最新更新的各開發階段比較分析,提供涵括了最新的新聞和發表之企業和研究機關開發中治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

白細胞介素1受體類型1;概要

白細胞介素1受體類型1;治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀
  • 企業開發中的產品
  • 大學/研究機關開發中的產品

治療藥的評估

  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • Paras Biopharmaceuticals Finland Oy
  • ProteoThera Inc
  • Swedish Orphan Biovitrum AB
  • XL-protein GmbH

藥物簡介

暫停中的產品

開發中止的產品

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC1543TDB

Summary:

Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) pipeline Target constitutes close to 9 molecules. Out of which approximately 8 molecules are developed by companies and remaining by the universities/institutes. The latest report Interleukin 1 Receptor Type 1 - Pipeline Review, H1 2018, outlays comprehensive information on the Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) - Interleukin 1 receptor, type I (IL1R1) or CD121a is an interleukin receptor encoded by IL1R1 gene. It plays an important role in many cytokine-induced immune and inflammatory responses. It mediates activation of NF-kappa-B, MAPK and other pathways. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 1, 4 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Immunology, Oncology, Gastrointestinal, Respiratory, Cardiovascular, Central Nervous System, Dermatology and Musculoskeletal Disorders which include indications Inflammation, Rheumatoid Arthritis, Ulcerative Colitis, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Advanced Malignancy, Asthma, Atopic Dermatitis, Bronchiolitis Obliterans, Cancer Anorexia-Cachexia Syndrome, Crohn's Disease (Regional Enteritis), Gouty Arthritis (Gout), Inflammatory Bowel Disease, Limited/Distal Colitis, Metastatic Breast Cancer, Metastatic Cancer, Mucocutaneous Lymph Node Syndrome (Kawasaki Disease), Myelodysplastic Syndrome, Myocarditis, Osteoarthritis Pain, Pain, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Solid Tumor and Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease).

Furthermore, this report also reviews key players involved in Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1)
  • The report reviews Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) - Overview
    • Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) - Companies Involved in Therapeutics Development
    • Immune System Key Ltd
    • Onspira Therapeutics Inc
    • Paradigm Biopharmaceuticals Ltd
    • Paras Biopharmaceuticals Finland Oy
    • ProteoThera Inc
    • Ribomic Inc
    • Swedish Orphan Biovitrum AB
    • XL-protein GmbH
  • Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) - Drug Profiles
    • anakinra - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • anakinra biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Fusion Protein to Antagonize IL-1R1 for Inflammation - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IP-1510 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Nerofe - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Protein to Antagonize IL1B for Bronchiolitis Obliterans - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PRT-1000 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RBM-009 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • XL-130 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) - Dormant Products
  • Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) - Discontinued Products
  • Interleukin 1 Receptor Type 1 (CD121 Antigen Like Family Member A or Interleukin 1 Receptor Alpha or p80 or CD121a or IL1R1) - Product Development Milestones
    • Featured News & Press Releases
      • Apr 11, 2018: Kineret (anakinra) approved in the EU for the treatment of Still's disease
      • Mar 26, 2018: Drug reduces inflammation in stroke patients
      • Feb 23, 2018: Kineret (anakinra) receives a positive opinion from CHMP for the treatment of Still's disease
      • Nov 21, 2017: Successful Completion of Phase I Nerofe Trial on Solid Tumor
      • Nov 16, 2017: First patient randomized in a phase 3 study evaluating safety and efficacy of anakinra in the treatment of Still's disease
      • May 30, 2017: Kineret approved in Canada for the treatment of Neonatal-Onset Multisystem Inflammatory Disease
      • Jan 11, 2017: First patient randomized in a phase II study evaluating safety and efficacy of anakinra in the treatment of acute gout
      • Jun 06, 2016: Pfizer CentreOne to manufacture Sobi's Kineret drug substance
      • Apr 21, 2016: European patent granted on new formulation of Kineret (anakinra)
      • Feb 23, 2016: Sobi to initiate clinical development programs in acute gout and Still disease, and receives US patent on new formulation for Kineret (anakinra)
      • Nov 01, 2015: Immune System Key: Nerofe's Triple Action
      • Aug 19, 2015: Kineret receives Australian regulatory approval for use in Systemic Juvenile Idiopathic Arthritis
      • Apr 01, 2015: Immune System Key: Clinical Trial: Phase I Dose Escalation Completed Successfully With Exciting Results
      • Apr 23, 2014: First treatment for babies with ultra-rare spectrum of auto inflammatory diseases now available in UK
      • Dec 06, 2013: First treatment for infants with ultra-rare spectrum of auto inflammatory diseases licensed in UK
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H1 2018
  • Number of Products under Development by Therapy Areas, H1 2018
  • Number of Products under Development by Indications, H1 2018
  • Number of Products under Development by Indications, H1 2018 (Contd..1), H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Products under Development by Companies, H1 2018
  • Products under Development by Companies, H1 2018 (Contd..1), H1 2018
  • Number of Products under Investigation by Universities/Institutes, H1 2018
  • Products under Investigation by Universities/Institutes, H1 2018
  • Number of Products by Stage and Mechanism of Actions, H1 2018
  • Number of Products by Stage and Route of Administration, H1 2018
  • Number of Products by Stage and Molecule Type, H1 2018
  • Pipeline by Immune System Key Ltd, H1 2018
  • Pipeline by Onspira Therapeutics Inc, H1 2018
  • Pipeline by Paradigm Biopharmaceuticals Ltd, H1 2018
  • Pipeline by Paras Biopharmaceuticals Finland Oy, H1 2018
  • Pipeline by ProteoThera Inc, H1 2018
  • Pipeline by Ribomic Inc, H1 2018
  • Pipeline by Swedish Orphan Biovitrum AB, H1 2018
  • Pipeline by XL-protein GmbH, H1 2018
  • Dormant Products, H1 2018
  • Dormant Products, H1 2018 (Contd..1), H1 2018
  • Discontinued Products, H1 2018

List of Figures

  • Number of Products under Development by Stage of Development, H1 2018
  • Number of Products under Development by Therapy Areas, H1 2018
  • Number of Products under Development by Top 10 Indications, H1 2018
  • Number of Products by Mechanism of Actions, H1 2018
  • Number of Products by Stage and Mechanism of Actions, H1 2018
  • Number of Products by Routes of Administration, H1 2018
  • Number of Products by Stage and Routes of Administration, H1 2018
  • Number of Products by Molecule Types, H1 2018
  • Number of Products by Stage and Molecule Types, H1 2018
Back to Top